Atopic Dermatitis
Latest News
Roflumilast foam effectively eases seborrheic dermatitis
The study evaluated a foam formulation of roflumilast, a PDE4 inhibitor that is available for topical use in a cream formulation that was recently...
Latest News
VTE risk not elevated in AD patients on JAK inhibitors: Study
The labels of JAK inhibitors include a boxed warning describing an increased risk of “serious heart-related events such as heart attack or stroke...
Latest News
Vitamin D supplements during pregnancy may protect infants from atopic eczema
“Our data provide the first randomized controlled trial evidence of a protective effect of antenatal cholecalciferol supplementation on risk of...
Conference Coverage
Topical ruxolitinib quickly relieves atopic dermatitis itch in Black patients
Ruxolitinib cream provides quick itch relief for Black patients with atopic dermatitis, researchers report.
Conference Coverage
Cultural humility required to optimize treatment of eczema patients with skin of color
Treating eczema in patients with skin of color requires cultural lens.
Latest News
Eczema causes substantial burden for many infants and preschoolers
INDIANAPOLIS –
From the Journals
Antibiotics during pregnancy may increase child’s risk for asthma and other atopic diseases
“It is estimated that 20%-25% of pregnant women receive at least one course of an antibiotic during this time period.”
Latest News
Introduce allergens early, say French allergists
For all newborns, regardless of whether they have a history of atopic or nonatopic dermatitis, food diversification is now recommended from 4...
Conference Coverage
Atopic dermatitis: Options abound, and more are coming
Do patients fit best in the topical or systemic bucket?
Conference Coverage
Therapeutic patient education can help with adherence to treatment
Therapeutic patient education is recommended for children and adults with moderate to severe AD in the 2020 European Task Force on Atopic...
Latest News
FDA approves dupilumab for children with eczema aged 6 months to 5 years
The approval makes dupilumab the first biologic available in the United States to treat atopic dermatitis in this age group.